This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) combined with immune cells (IC01) in subjects with advanced Gastrointestinal cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.
Incidence and duration of all the adverse events will be recorded. The severity of adverse events will be evaluated according to NCI-CTCAE v4.03 criteria.
Time frame: Day 0 to 4 months after the end of the trial
Tumor Response of the treatment in patients with advanced gastrointestinal cancer.
Response Evaluation Criteria in Solid Tumors (RECIST) from the NCI will be used for assessment of radiographic response.
Time frame: Before treatment and Day 28 to 4 months after the end of the treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.